Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer

Investigational New Drugs

Volumn 25, Issue 6, 2007, Pages 559-564

  Campagnoli, Elisabetta ^a   Garassino, Isabella ^a   Santoro, Armando ^a   De Vincenzo, Fabio ^a   Zucali, Paolo Andrea ^a   Ceresoli, Giovanni Luca ^a   Lutman, Fabio Romano ^a   Alloisio, Marco ^a   Soto Parra, Hector Josè ^b   Cavina, Raffaele ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b GARIBALDI HOSPITAL   (Italy)

Author keywords

Advanced NSCLC; Cisplatin; Oral chemotherapy; Oral vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG DERIVATIVE; NAVELBINE; VINBLASTINE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 39549099796     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-007-9067-2     Document Type: Article

References (28)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) For the eastern cooperative oncology group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
2. Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer. A South West Oncology Group trial. J Clin Oncol 19:3210-3218 (Pubitemid 32591438)
3. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M (2002) For the Italian Lung Cancer Project: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20(21):4285-4291 (Pubitemid 35266288)
4. Depierre A, Chastang CI, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badri N, Besenval M (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann Oncol 5:37-42 (Pubitemid 24049852)
5. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S et al. (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin and vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12(2):360-367
6. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao M-S, Gandara D, Kesler K, Demmy T, Shepherd F (2005) For the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352:2589-2597
7. The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360
8. Douillard J, Rosell R, Delena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet P-J, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719-727 (Pubitemid 44283661)
9. Gebbia V, Galetta D, Caruso M (2005) Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine with cisplatin in advanced non-small cell lung cancer: end results of a phase III trial. Lung Cancer 49(Suppl 2):S32
10. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643-1649 (Pubitemid 34070598)
11. Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, Etienne P-L, Seebacher C, Grivaux M, Ojala A, Aubert D, Lefresne F (2003) Oral vinorelbine in combination with cisplatin: a novel active regimen in advance non-small cell lung cancer. Ann Oncol 14:1634-1639 (Pubitemid 37455812)
12. De Lena M, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J (2005) Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 48:129-135 (Pubitemid 40381009)
13. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110-115 (Pubitemid 27021524)
14. Nolè F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U (1999) Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Ann Oncol 10(8):993-996 (Pubitemid 29424583)
15. Magagnoli M, Balzarotti M, Sarina B, Castagna L, Timofeeva I, Nozza A, Bertuzzi A, Siracusano L, Santoro A (2001) Mobilizing potential of IGEV (ifosfamide, gemcitabine, vinorelbine) chemotherapy in refractory/relapsed Hodgkin's disease (HD). Bone Marrow Transplant 27(Suppl 1):S269
16. Zucali PA, Soto Parra HJ, Cavina R, Campagnoli E, Latteri F, Ginanni V, Biancofiore G, Ferrari B, Morenghi E, Santoro A (2003) Results of a dose-findings study with a short-schedule cisplatin (P) and Vinorelbine (V) in non-small cell lung cancer (NSCLC): an attempt to improve feasibility and compliance. Proc Am Soc Clin Oncol 22:2846a
17. National Cancer Institute (2003) Common toxicity criteria, version 3.0. National Cancer Institute, Bethesda, MD
18. AJCC (2002) Cancer staging manual, 6th edn. Springer, New York (March)
19. Fleming TR (1982) One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143-151
20. American Society of Clinical Oncology (2004) Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 22:330-353
21. Souquet PJ, Tan EH, Rodriguez Pereira J, Van Klaveren R, Price A, Gatzemeier U, Jaworski M, Burillon JP, Aubert D (2002) GLOB1: a phase III trial comparing the combination of vinorelbine and cisplatin (NP) versus vinorelbine, ifosfamide and cisplatin (NIP) in metastatic non-small cell lung cancer patients (NSCLC). Ann Oncol 13:1853-1861
22. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer. J Clin Oncol 16:2459-2465 (Pubitemid 28309041)
23. Fossella F, Pereira JR, von Pawel J Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024 (Pubitemid 46606280)
24. Gebbia V, Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 4:1-14
25. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O' Brien M, Depierre A (2001) A multicenter randomized phase II study of oral versus intravenous vinorelbine in advanced non-small cell lung cancer patients. Ann Oncol 12:1375-1381 (Pubitemid 33100241)
26. O'Brien MER, Szczesna A, Karnicka H, Zatloukal P, Eisen T, Hartman W, Kasan P, Longerey B, Lefresne F (2004) Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 15:921-927 (Pubitemid 39004348)
27. Chen Y-M, Yu C-J, Yang C-H, Perng R-P, Tsai C-M, Shih J-F, Cheng A-L, Lefresne F, Barbier M, Pouget J-C, Yang P-C (2007) A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung cancer. Lung Cancer 56:89-95 (Pubitemid 46356641)
28. Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2004) Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 43:223-240 (Pubitemid 38114752)